Can Cipla's Respiratory Business Offset the US Generics Risks?
The Cipla respiratory products have a good domestic base because of the inhalers production capabilities as well as the presence of chronic drugs. However, considering that North America accounts for about 22% of the total revenue, the revival in the US market is extremely vital for ensuring that the company remains risk-free. The success of Cipla in using their good domestic base will help in coping with the changes in the US generic market.
Cipla was trading at around ₹1,397 , with a market capitalization of roughly ₹1,12,874 crore . Its 52-week range is ₹1,166–₹1,673 , while the current P/E is around 31x .
The stock is therefore well below its 52-week high, while analysts remain divided on how quickly the US earnings profile can recover. Recent targets include ₹1,450 from Prabhudas Lilladher, ₹1,592 from Deven Choksey and ₹1,610 from ICICI Securities . These are analyst estimates, not assured outcomes.
Respiratory Is Still One of Cipla’s Biggest Strengths
Cipla has built a sizeable respiratory franchise over decades. In India, the company ranks No. 1 in respiratory therapy with more than 25% market share , according to its FY26 annual report. Foracort remains one of its leading brands, while Cipla is also the third-largest respiratory player in North America by prescriptions.
The latest Q1 FY27 data reinforces this position. Respiratory was among the company's key chronic therapies delivering double-digit growth, while Foracort remained the largest respiratory brand in the Indian pharmaceutical market and a ₹1,000 crore-plus franchise. This gives Cipla an important advantage because respiratory medicines often involve both the drug and the delivery device .
Why Is the Indian Respiratory Franchise Difficult to Replicate?
The moat is not simply a large product portfolio. Cipla has developed capabilities across inhaler devices, drug-device combinations, manufacturing, patient education and physician engagement . Historically, analysts have highlighted the complexity of inhaler manufacturing and the higher barriers to entry compared with conventional oral generics.
A brand aspect exists as well. Cipla has invested a number of years in creating awareness about the inhalation therapy with campaigns like Berok Zindagi, while its existing brands have formed ties with prescribers.
Whereas Cipla boasts a market share that is greater than 25% in the entire respiratory prescription drug market of India, reports by the industry put the company’s market dominance at an even higher level in the inhalation category, accounting for 70% of the total market. This implies a clear presence of a moat that has been developed over the years.
The Domestic Business Provides a Second Earnings Base
The chronic portfolio composition of the One India business unit of Cipla rose to 60.4%. The One India business also witnessed record revenues for the quarter at ₹3,452 crore, which is an increase of 12% from the previous year.
IQVIA data for Q1 FY27 reveals that Cipla's key chronic segments witnessed healthy double-digit growth, including respiratory at 15%, anti-diabetes by 43%, cardiac at 20%, and urology at double digits.
The US Story Is More Complicated
Cipla's pipeline for the remainder of FY27 includes four significant filings: three respiratory assets (including generic Advair) and one large peptide product. Crucially, two of these respiratory products are filed from Cipla’s US manufacturing network, while the third originates from its Goa facility.
The timely clearances and launches will be vital for Cipla to achieve the US exit rate of $1 billion. Nevertheless, the analysts are still wary; according to Prabhudas Lilladher, the US revenue target is likely to be $775 million for FY27 and $925 million for FY28 based on the timing of approvals.
ICICI Securities also described the recovery as dependent on timely US launches and maintained a ₹1,610 target based on its FY28 estimates. These differing estimates show how dependent the investment case is on execution.
Generic Ventolin Is Already Starting to Ramp Up
One of the main opportunities is generic Ventolin .Cipla launched gVentolin in the US during Q1 and has started commercial shipments, with the company expecting volumes to increase as supply scales.
Cipla also remains the No. 1 player in the US Albuterol MDI market with 21% market share , according to IQVIA data for June 2026.This is where the respiratory capability becomes important: Cipla already has an established position in the category, rather than entering an unfamiliar market from scratch.
Regulatory Risk Has Not Disappeared
Cipla's US manufacturing network remains another area to watch.The US FDA completed a routine inspection at the Goa facility , which was classified as VAI . The Invagen facility in New York received one Form 483 observation , while Cipla was also awaiting reinspection of its Indore facility.
Management said the New York observation affects smaller products and is not linked to the three major respiratory launches already inspected.
So the regulatory situation is not an immediate shutdown-type issue based on the disclosures, but approvals and manufacturing compliance remain important for the US pipeline.
Tariffs Add Another Layer of Uncertainty
The latest US tariff announcement has added a longer-term risk for Indian generic exporters.Under the announced schedule, imported generic medicines remain tariff-free for two years from August 2026, before a 100% tariff from August 2028 and 200% from August 2029 unless companies adjust their manufacturing footprint.
Cipla has already stated that 35%-40% of its business comes from the US , giving it some existing local manufacturing capability. That could provide flexibility, although the final impact will depend on which products are manufactured where and how the policy develops.
The Financial Base Remains Strong
Cipla’s numbers for Q1 FY27 stood at ₹7,119 crore in sales, ₹1,192 crore in EBITDA, and ₹789 crore in PAT. Its margin of EBITDA fell short of its forecasted margin of 18.5%-20% for FY27 owing to the costs of launch-readiness, increased war costs related to transit supply chain, and change in product mix. However, Cipla spent ₹486 crore (6.8% of revenues) on R&D costs to emphasize capital spending on filing peptides and respiratory products.
Can Respiratory Offset the US Generic Risks?
The answer depends on which side of Cipla's business an investor is focusing on.The Indian respiratory franchise is established, with strong market share, major brands such as Foracort and deep drug-device capabilities.
The US respiratory opportunity , meanwhile, is more of a rebuilding story. gVentolin has started shipping, while additional respiratory and peptide launches could materially change the earnings profile if approvals and commercial ramp-ups go as planned.
However, the dangers are no less obvious: the revenue concentration of the US at 22%, the dependency on a limited number of highly valuable goods, manufacturing inspections, competition, and the new tariff system.
For now, Cipla's situation is therefore best viewed as a balance between a relatively entrenched Indian respiratory franchise and a US business undergoing portfolio renewal . The next few quarters should provide more evidence on whether new respiratory launches can replace lost products while preserving margins.
The stock's current valuation already reflects both the strength of the domestic franchise and expectations of a US recovery. The central issue is whether that recovery happens quickly enough, and with enough profitability, to support the valuation.